Since JAK2 inactivates PP2A and reactivation of PP2A leads to depletion of the LSCs by inhibiting STAT5, a synergism of JAK2 inhibitors and PP2A activators might be effective in the treatment of CML [190]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.